Parallax Volatility Advisers
PCRX icon

Parallax Volatility Advisers’s Pacira BioSciences PCRX Stock Holding History

Parallax Volatility Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,100
Closed -$58.4K – 2002
2024
Q4 		$58.4K Sell
3,100
-7,000
-69% -$123K ﹤0.01% 1773
2024
Q3 		$152K Buy
+10,100
New +$173K ﹤0.01% 1723
2019
Q2 		– Sell
-18,000
Closed -$685K – 3384
2019
Q1 		$685K Buy
+18,000
New +$703K ﹤0.01% 1406
2017
Q2 		– Sell
-150,000
Closed -$6.84M – 3455
2017
Q1 		$6.84M Buy
+150,000
New +$6.48M 0.01% 479

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Parallax Volatility Advisers's PCRX Position: Q1 2025 in Review

Parallax Volatility Advisers sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 5,357 shares — an estimated $101K sold.

Parallax Volatility Advisers first reported a position in PCRX in Q4 2017 and held it in 8 quarters. The position peaked at $406K in Q4 2018. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Parallax Volatility Advisers reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,357 Pacira BioSciences shares in Q1 2025, an estimated $101K.
  • Parallax Volatility Advisers first reported a position in Pacira BioSciences in Q4 2017 and held it in 8 quarters.
  • Parallax Volatility Advisers's Pacira BioSciences position peaked at $406K in Q4 2018.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Parallax Volatility Advisers's 13F filing for Q1 2025, filed 15 May 2025.